1. Introduction {#s1}
===============

Despite major improvements in stents material, interventional techniques and drug therapies, in-stent restenosis (ISR) after stents implantation is still 5%--15%, even in drug-eluting stents (DESs) era.[@b1]--[@b3] The predictive performance of conventional risk factors (such as age, hypertension, diabetes mellitus, smoking, C reaction protein, severe calcification and diffuse lesions, long and multiple stents, etc) seems to be not satisfying. To date, we still lack effective and accurate methods to identify who are at high risk of ISR, thereby can\'t offer them with relevant drug therapy before repeated revascularization. Epicardial adipose tissue (EAT) is directly deposited around the pericardium and coronary artery. By autocrine and paracrine means, it can generate various kinds of proinflammatory mediators and free fatty acids.[@b4],[@b5] Those biological indicators can affect the state of endothelial function, promote inflammation and oxidative stress, and aggravate proliferation and migration of smooth muscle cells.[@b4]--[@b8] As we know, endothelial dysfunction, inflammation, oxidative stress, smooth muscle cells proliferation and migration are all key points that associated with coronary atherosclerosis and ISR.[@b9]--[@b12] Multiple clinical researches have shown that increased EAT deposition plays an important role in the development and progression of atherosclerosis, metabolic syndrome and cardiac events.[@b13]--[@b16] Whether increased EAT deposition may affect the incidence of ISR is currently unclear. In this study, we sought to identify whether there is a relationship between ISR and EAT volume detected by coronary computed tomography angiography (CCTA).

2. Methods {#s2}
==========

2.1. Study population {#s2a}
---------------------

From May 2013 to April 2014, a total of 364 patients who underwent 64-slice CCTA examination for the evaluation of suspected coronary artery disease, and subsequently underwent percutaneous coronary intervention (PCI) in the Chinese PLA General Hospital for the first time within one month, then accepted coronary angiography (CA) follow-up for ISR examination in 9--15 months, were retrospectively included in this study. The inclusion criteria were as follows: age ≥ 18 years; accepted selective PCI in our hospital for the first time after CCTA examination within one month; all stents implanted were DESs; stents diameter was 2.5--4.0 mm; the time interval of CA was 9--15 months. The exclusion criteria were as follows: severe heart dysfunction or severe left ventricle dysfunction (left ventricle ejection \< 30%); severe renal insufficiency (serum creatinine \> 1.5 mg/dL); previous coronary artery bypass graft (CABG) or previous PCI; CCTA images with motion artifact or impaired image quality. The study was approved by our institutional review board. All patients were fully explained the procedure of the examination, and the written informed consents were obtained.

2.2. CCTA imaging and analysis {#s2b}
------------------------------

All patients underwent a dual-source CT scanner (Somatom Definition Flash, Siemens Healthcare, Forchheim, Germany) for the evaluation of suspected coronary artery disease. Patients were instructed in breath-holding technique before the scan to minimize the breathing artifact. All patients without contraindications were given a 0.5 mg nitroglycerin sublingually 3 min before the scan. Patients with heart rate (HR) \> 70 beats/min were intravenously given a 50--100 mg esmolol hydrochloride injection before the scan unless contraindicated. The scan range was from the carina or the pulmonary artery segment down to 1 cm below the diaphragm. Electrocardiograph was continuously monitored throughout the entire scan. Dual-head power injector (SCT 210, Medrad, USA) and the nonionic contrast medium (Ultravist^®^, 370 mgI/mL, Schering AG, Guangzhou, China) were used during the scan.

Prospectively ECG-triggered high-pitch spiral acquisition or prospectively ECG-triggered sequential acquisitions were used to acquire the CCTA images. The scan parameters were as follows: detector collimation 2 × 128 × 0.6 mm; gantry rotation time 0.28 ms; slice thickness 0.6 mm; tube voltage 80 to 120 kV (modified by Care kV technique to minimize the radiation dose) and tube current 290 to 560 mAs/rotation (modified by CareDose 4D technique to minimize the radiation dose); pitch was 3.4 for flash acquisition and 0.17--0.24 depending on HR for prospectively acquisition.

All CCTA data were sent to a dedicated software (QAngio CT Research Edition version 2.1.9.1, Medical Imaging Systems, Leiden, the Netherlands) for plaque analysis. Two skilled radiologists unaware of the patients\' clinical information independently evaluated the CCTA data. Disagreements analysis in all CCTA images between the two readers were resolved by consensus reading. Coronary artery classification was evaluated referring the 15 segments model of the American Heart Association.[@b17] Patients with coronary stenosis greater or equal to 75% were defined as ones that should accepted CA examination and further stent implantation.

2.3. EAT volume measurement {#s2c}
---------------------------

Total EAT volume was measured by two experienced radiologists using the same sets of images acquired from CCTA. The radiologists were blinded to the purpose of the study and the patients\' anthropometric data. A cursor pointer was used to manually trace the pericardial contour with 0.75-mm-thick reconstructed axial slices ([Figure 1](#jgc-13-09-768-g001){ref-type="fig"}). Pericardium contour was traced for every 10 mm starting from the lower visible level of pulmonary artery bifurcation until the last slice where pericardium is still visible ([Figure 2](#jgc-13-09-768-g002){ref-type="fig"}).[@b18] The pericardium contour is extrapolated by the software (Syngo Volume, Siemens Medical Solutions) for the non-traced slices and rechecked by the operator. EAT was identiﬁed using the adipose tissue attenuation references between --190 and --30 Hounsﬁeld unit.[@b19] Pericardial adipose fat (fat depot outside the visceral pericardium and on the external surface of the parietal pericardium) were excluded from analysis.

The total EAT volume were evaluated by two independent radiologists who were blinded to the other\'s measurements for the assessment of inter-observer agreements in 50 randomly selected patients. The intra and inter-observer correlation coefficients for EAT volume measurements were 0.96 and 0.92, respectively.

2.4. Coronary angiography and stent implantation {#s2d}
------------------------------------------------

Patients with coronary stenosis greater or equal to 75% accepted CA after CCTA examination within one month. Patients who accepted elective PCI with coronary stent implantation in our hospital after CCTA for the first time were enrolled in this study. Experienced cardiologists performed PCIs and DESs implantation using standard techniques via the right radial (or femoral) artery in all enrolled patients. During the PCI procedure, direct stenting, balloon pre-dilatation or post-dilatation techniques were used according to the cardiologist\'s decision. The ratio of stent diameter to distal reference vessel diameter was 1: 1 to 1.1: 1, and stent delivery pressure was at least 13 atm. The available stent lengths were 10--36 mm, and the stent diameters were 2.5, 3.0, 3.5, and 4.0 mm. All results of coronary angiography were analyzed at an independent core laboratory. The quantitative coronary angiography (QCA) software package from Medis CMS (Leiden, the Netherlands) was used for imaging analysis.

![Example of EAT volume quantification by CCTA.\
(A): EAT was deﬁned as the adipose tissue within the visceral layer of the pericardium (arrows on A); (B): Total EAT volume was quantiﬁed by manually tracing the pericardium on the contrast-enhanced CT imaging, then calculated and highlighted with a threshold of --30 to --190 HU by the software (Syngo Volume, Siemens Medical Solutions). Purple area represent EAT. CCTA: coronary computed tomography angiography; EAT: epicardial adipose tissue.](jgc-13-09-768-g001){#jgc-13-09-768-g001}

![Measurement of EAT volume.\
The axial slices used for pericardial tracking is shown in a coronal projection. EAT was identiﬁed within the limits of pericardium sac using the adipose tissue attenuation references (--30 to --190 HU). Pericardium contour was traced for every 10 mm, starting from the lower visible level of pulmonary artery bifurcation until the last slice where pericardium is still visible. Final EAT volume quantiﬁcation was calculated as the sum of all slices fat values. EAT: epicardial adipose tissue.](jgc-13-09-768-g002){#jgc-13-09-768-g002}

2.5. Drug treatment and CA follow-up at one year {#s2e}
------------------------------------------------

All patients accepted conventional anti-atherosclerosis treatments, including one year dual antiplatelet therapy (aspirin 100 mg/day and clopidogrel 75 mg/day) and statin treatment. All patients accepted CA examination at an interval of 9--15 months to follow up ISR and coronary atherosclerosis state. The primary end point of this study was angiographic ISR, deﬁned as ≥ 50% luminal diameter narrowing of the stented or peri-stent segment (defined as a length of 5 mm proximal and distal to the stent edge); patent stent was defined as \< 50% or no stenosis.[@b20]

2.6. Statistical analysis {#s2f}
-------------------------

Continuous variables were presented as mean ± SD and categorical variables were presented as *n* (%). Continuous variables with normal distribution were compared using unpaired Student\'s *t*-test and with abnormal distribution were compared using Mann-Whitney *U* test or Wilcoxon\'s signed-rank test. Categorical variables were compared using Chi-squared test or Fisher\'s exact test if necessary. Simple correlations between clinical parameters and EAT volume were evaluated using Spearman\'s correlation coefficient. Intra and inter-observer correlations were assessed using intraclass correlation coefficients in 50 randomly selected patients. Variables (including clinical, angiographic variables and EAT volume) known or suspected to be associated with the presence of ISR were assessed using univariable and multivariable logistic regression analysis. A *P*-value \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS (version 17.0 for Windows, SPSS, Inc., Chicago, IL, USA).

3. Results {#s3}
==========

3.1. Clinical characteristics {#s3a}
-----------------------------

In the final analysis, 364 patients received a mean of 12.7 ± 2.6 months CA follow-up. During the one year CA follow-up, ISR was seen in 46 (12.6%) patients, and intima hyperplasia was seen in 30 (8.2%) patients.

As shown in [Table 1](#jgc-13-09-768-t01){ref-type="table"}, there were no significant differences in variables such as age, gender, body weight, body mass index (BMI), systolic blood pressure, hypertension, hyperlipidemia, family history of coronary artery disease, medications, and laboratory and echocardiography data (all *P* \> 0.05). Significantly differences were observed between ISR and Non-ISR group in terms of diastolic blood pressure (72.9 ± 10.4 mmHg *vs*. 76.9 ± 11.4 mmHg, *P* = 0.025), patients with diabetes mellitus (43.5% *vs*. 25.8%, *P* = 0.013), and current smoking (54.3% *vs*. 32.1%, *P* = 0.005). Patients with ISR had a significantly higher EAT volume compared to patients without ISR (154.5 ± 74.6 mL *vs*. 131.0 ± 52.2 mL, *P* = 0.008).

The basic angiographic parameters were listed in [Table 2](#jgc-13-09-768-t02){ref-type="table"}. ISR group showed more stents planted compared to non-ISR group (2.0 ± 1.0 stents *vs*. 1.7 ± 0.8 stents, *P* = 0.022). Significantly differences were observed between ISR and Non-ISR group in terms of stent length (26.1 ± 6.1 *vs*. 22.4 ± 5.6 mm, *P* = 0.003).

###### Clinical characteristics of the study population.

  Variable                          ISR group (*n* = 46)   Non-ISR group (*n* = 318)   *P* value
  -------------------------------- ---------------------- --------------------------- -----------
  Age, yrs                              61.9 ± 12.7               60.3 ± 11.5            0.374
  Gender, male                           32 (69.6%)               226 (71.1%)            0.834
  Body weight, kg                       72.2 ± 15.7               72.7 ± 10.7            0.831
  BMI, kg/m^2^                           25.5 ± 4.1               25.9 ± 2.9             0.545
  Systolic blood pressure, mmHg         134.4 ± 21.1             137.3 ± 17.1            0.294
  Diastolic blood pressure, mmHg        72.9 ± 10.4               76.9 ± 11.4            0.025
  Cardiovascular risk factors                                                         
   Diabetes mellitus                     20 (43.5%)               82 (25.8%)             0.013
   Hypertension                          31 (67.4%)               207 (65.1%)            0.760
   Hyperlipidemia                        22 (47.8%)               123 (38.7%)            0.236
   Current smoking                       25 (54.3%)               102 (32.1%)            0.005
   Family history of CAD                 21(45.7%)                152(47.8%)             0.785
  Medication                                                                          
   Statins                               35 (76.1%)               230 (72.3%)            0.592
   β-blockers                            33 (71.7%)               209 (65.7%)            0.419
   ACEIs/ARBs                            19 (41.3%)               147 (46.2%)            0.531
   CCB                                   18 (39.1%)               124 (39.0%)            0.986
  Laboratory data                                                                     
   On admission                                                                       
    Total cholesterol, mmol/             4.1 ± 1.1                 4.3 ± 1.0             0.358
    Triglycerides, mmol/L                1.5 ± 0.7                 1.7 ± 1.1             0.102
    LDL-C, mmol/L                        2.4 ± 1.0                 2.5 ± 0.9             0.275
    HDL-C, mmol/L                        1.0 ± 0.2                 1.1 ± 0.3             0.270
    Creatinine, mg/dL                   80.7 ± 56.6               75.4 ± 19.4            0.213
    FBG, mmol/L                          6.8 ± 2.6                 6.6 ± 2.0             0.543
   At follow-up                                                                       
    Total cholesterol, mmol/L            3.1 ± 0.7                 3.3 ± 1.0             0.191
    Triglycerides, mmol/L                1.4 ± 0.8                 1.5 ± 0.9             0.476
    LDL-C, mmol/L                        1.9 ± 0.6                 2.0 ± 0.8             0.416
    HDL-C, mmol/L                        1.0 ± 0.3                 1.1 ± 0.4             0.104
  Echocardiography                                                                    
   LVDd, mm                              45.6 ± 6.1               45.6 ± 4.6             0.957
   LVDs, mm                              31.9 ± 5.6               31.3 ± 4.4            0\. 389
   EF, %                                 57.1 ± 7.3               58.7 ± 7.2             0.159
  CT finding                                                                          
   Epicardial fat volume, mL            154.5 ± 74.6             131.0 ± 52.2            0.008

Data are presented as mean ± SD or *n* (%). ACEIs/ARBs: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; BMI: body mass index; CAD: coronary artery disease; CCB: calcium channel blocker; CT: computed tomography; EF: ejection fraction; FBG: fasting blood-glucose; HDL-C: high density lipoprotein cholesterol; ISR: in-stent restenosis; LDL-C: low density lipoprotein cholesterol; LVDd: left ventricular diastolic diameter; LVDs: left ventricular systolic diameter.

###### Basic angiographic data of the study population.

  Variable                     ISR group (*n* = 46)   Non-ISR group (*n* = 318)   *P* value
  --------------------------- ---------------------- --------------------------- -----------
  Target vessels                                                                 
   LM                                4 (8.7%)                 8 (2.5%)              0.122
   LAD                              37 (80.4%)               244 (77.0%)            0.846
   LCX                              16 (34.8%)               96 (30.2%)             0.891
   RCA                              35 (76.1%)               223 (70.1%)            0.854
   Multi-vessels                    10 (21.7%)               47 (14.8%)             0.225
  Lesions                                                                        
   Bifurcation                      8 (17.4%)                52 (16.4%)             0.859
   CTO                              7 (15.2%)                48 (15.1%)             0.983
  Stents parameter                                                               
   Number of stents, *n*            2.0 ± 1.0                 1.7 ± 0.8             0.022
   Mean stent diameter, mm          2.9 ± 0.4                 3.1 ± 0.7             0.059
   Mean stent length, mm            26.1 ± 6.1               22.4 ± 5.6             0.003
   Sirolimus                        70 (76.1%)               308 (74.9%)            0.818
   Paclitaxel                       22 (23.9%)               103 (25.1%)            0.818
  Stenting technique                                                             
   Pre-dilation                     43 (93.5%)               308 (96.9%)            0.466
   Direct stenting                   3 (6.5%)                 10 (3.1%)             0.466
   Post-dilation                    36 (78.3%)               254 (79.9%)            0.799
   CA follow-up interval, m         12.7 ± 2.1               13.1 ± 3.4             0.438

Data are presented as mean ± SD or *n* (%). CA: coronary angiography; CTO: chronic total occlusion; LAD: left anterior descending; LCX: left circumflex coronary artery; LM: left main artery; RCA: right coronary artery.

3.2. Relationship between clinical parameters and EAT volume {#s3b}
------------------------------------------------------------

EAT volume showed significant correlations with BMI (*r* = 0.348, *P* \< 0.001) and diabetes mellitus (*r* = −0.127, *P* = 0.016) in all 364 patients. EAT volume also showed significant correlations with BMI both in ISR and Non-ISR group (*r* = 0.379, *P* = 0.009 and *r* = 0.351, *P* \< 0.001 respectively). In ISR group, left ventricular diastolic diameter (*r* = 0.358, *P* = 0.015), left ventricular systolic diameter (*r* = 0.354, *P* = 0.016) and ejection fraction (*r* = −0.308, *P* = 0.037) were also correlated with EAT volume. While, significant correlations were showed among age (*r* = 0.210, *P* \< 0.001), gender (*r* = 0.282, *P* \< 0.001), total cholesterol (*r* = −0.170, *P* = 0.003), triglycerides (*r* = 0.261, *P* \< 0.001), high density lipoprotein cholesterol (HDL-C) (*r* = −0.251, *P* \< 0.001) and low density lipoprotein cholesterol (LDL-C) (*r* = −0.130, *P* = 0.024) in Non-ISR group.

3.3. The relationship between EAT volume and in-stent restenosis {#s3c}
----------------------------------------------------------------

In the univariate logistic regression analysis, the conventional predictors for ISR such as diabetes mellitus, current smoking, diastolic blood pressure, LDL-C at follow-up, mean stent length, and mean stent diameter were all statistically significant risk factors for ISR ([Table 3](#jgc-13-09-768-t03){ref-type="table"}). The unadjusted odds ratio was 1.007 (95% CI: 1.002−1.012, *P* = 0.010) for EAT volume to predict ISR ([Table 3](#jgc-13-09-768-t03){ref-type="table"}).

In the multivariable logistic regression analysis to determine the predictors of ISR, after adjusted for conventional cardiac risk factors and the angiographic data (mean stent length and mean stent diameter), the odds ratio was 1.009 (95% CI 1.002−1.016, *P* = 0.009) for EAT volume to predict ISR ([Table 4](#jgc-13-09-768-t04){ref-type="table"}).

###### Univariate logistic regression analysis of predictors for ISR.

  Variable                     OR        95% CI      *P* Value
  -------------------------- ------- -------------- -----------
  Age                         1.012   0.985--1.012     0.373
  Diabetes mellitus           2.214   1.173--4.177     0.014
  Current smoking             2.521   1.348--4.715     0.004
  Diastolic blood pressure    0.968   0.940--0.996     0.026
  LDL-C on admission          0.820   0.574--1.171     0.274
  LDL-C at follow-up          0.552   0.331--0.922     0.023
  Mean stent length           1.122   1.057--1.191     0.001
  Mean stent diameter         0.288   0.115--0.720     0.008
  Epicardial fat volume       1.007   1.002--1.012     0.010

ISR: in-stent restenosis; LDL-C: low density lipoprotein cholesterol.

###### Multivariate logistic regression analysis of predictors for ISR at approximately one year after PCI.

  Variable                     OR        95% CI      *P* Value
  -------------------------- ------- -------------- -----------
  Age                         0.988   0.956--1.020     0.461
  Diabetes mellitus           2.256   1.012--5.030     0.047
  Current smoking             1.706   0.758--3.838     0.197
  Diastolic blood pressure    0.972   0.940--1.005     0.091
  LDL-C on admission          0.906   0.585--1.405     0.906
  LDL-C at follow-up          0.383   0.191--0.769     0.007
  Mean stent length           1.122   1.048--1.201     0.001
  Mean stent diameter         0.217   0.066--0.710     0.012
  Epicardial fat volume       1.009   1.002--1.016     0.009

ISR: in-stent restenosis; LDL-C: low density lipoprotein cholesterol; PCI: percutaneous coronary intervention.

4. Discussion {#s4}
=============

The present study of 364 patients with DESs implantation showed that patients with ISR had increased EAT deposition compared with patients without ISR. The major finding was that the association of EAT volume with ISR in patients with DESs, was independent of conventional cardiovascular risk factors, treatment factor and angiographic parameter (mean stent length and mean stent diameter). This study, to the best of our knowledge, was the first analysis aimed at finding out the relationship between EAT volume and the presence of ISR using CCTA as a non-invasive imaging method. A different group has already described that EAT is associated with ISR, but it used echocardiography, a much less sensitive tool to quantify EAT.[@b21] As we known, CCTA is now a recognized tool to quantify EAT volume because it can quantify the coronary atherosclerosis at the same time.

EAT is the adipose tissue deposited directly surrounding the major coronary arteries and their braches. Adipose tissue recently is found to be an endocrine organ which can secretes plenty of adipocytokines, free fatty acid and pro-inflammation markers.[@b4]--[@b6] Increased EAT deposition can cause superfluous pro-inflammation mediators secreted into the blood or paracrine to the adjacent tissue. Multiple exocrine and paracrine factors secreted by EAT can directly influence coronary artery wall homeostasis by altering the function of endothelial cells, arterial smooth muscle cells and macrophages. It can cause inflammation, oxidative stress, endothelial injury, vascular smooth muscle cells (VSMCs) proliferation and migration, lipid metabolic disorders and microphage infiltration in the adjacent coronary artery wall and other pathological changes.[@b4]--[@b6],[@b22]

The proliferation and migration of VSMCs is the main pathophysiological processes of coronary ISR. Increase EAT can secret plenty of factors that may promote (visfatin, resistin and angiopoietin-like protein, etc) or inhibit (adiponectin) VSMCs proliferation and migration. Visfatin can stimulate VSMCs proliferation via nicotinamide mononucleotide (NMN)-mediated ERK 1/2 and p38 signaling.[@b23] Angiopoietin-like protein secreted by peri-vascular adipose tissue can accelerate neointimal hyperplasia after endovascular injury.[@b24] Resistin could promote VSMC proliferation through activation of ERK1/2 and phosphatidylinositol 3-kinase (PI3K) pathways.[@b25] The role of adiponection on VSMC proliferation and migration is opposed to resistin.[@b26] Zhang, *et al*.[@b27] found that adiponectin could up-regulate the expression of mitofusin-2 (MFN2), inhibiting the Ras-Raf-ERK1/2 signaling pathway, which could lead to the inhibition of VSMC proliferation and the induction of VSMC apoptosis. Resistin also significantly increase p42/44 mitogen-activated protein kinase (MAPK) phosphorylation within rat VSMCs, whereas adiponectin inhibited resistin-induced MAPK phosphorylation.[@b26] Therefore, increased EAT deposition can cause imbalance between promoting and inhibiting pro-inflammation markers, which may finally affect the ISR by act on the proliferation and migration of VSMCs.

Inflammation also plays a pivotal role in the development of ISR by acting on the neointimal tissue at the sites of coronary stenting. In recent years, several studies have shown that ISR may be the result of neoatherosclerosis caused by the delayed re-enothelialization.[@b28] As researches showed that EAT from patients with CAD was with higher levels of interleukin (IL)-1β, IL-6, tumor necrosis factor α (TNF-α) and MCP-1 than patients without CAD.[@b29]--[@b31] Expression of these factors associated with inflammatory cells infiltrates may affect the development or progression of atherosclerosis. So, EAT may also accelerate the pathological process of ISR by promoting neoatherosclerosis via inflammation pathway.

Researches using drug treatments aimed at reducing EAT volume or improve inflammatory states of EAT have shown considerable results. A serial CCTA study recently have shown that intensive statin therapy can reduce the EAT volume of Europeans.[@b32] Simvastatin and pioglitazone combined treatment can reduce the inflammatory markers of epicardial adipose tissue of coronary patients with metabolic syndrome.[@b33] Low dose aspirin is reported to be associated with plasma chemerin levels and may reduce adipose tissue inﬂammation.[@b34] So treatments aimed at reducing the volume or improve the inflammation state of EAT may also reduce the incidence of ISR. Previous researches reported have shown that EAT was significant associated with BMI.[@b30] In our study, a strong relationship between epicardial tissue and BMI was also seen either in ISR patients or non-ISR patients. Hence, losing weight may also lower EAT volume, change the pathological state and reduce the pro-inflammation mediators secreted by EAT, which may finally result in lower incidence of ISR and cardiovascular risk.

In conclusions, this study demonstrated that EAT is an independent predictor for ISR in approximately 1-year follow-up using CCTA as a non-invasive imaging method. Increased EAT deposition may be an early warning of ISR. Thus we should pay more attentions to increased EAT deposition for patients with DESs after PCI. Treatments aimed at reducing EAT volume or improve inflammatory states of EAT may reduce the incidence of ISR.

There were some limitations of this study. First, the sample size was not large enough and this study was a single-center investigation. The predictive role of conventional risk factors in ISR, such as ages, diabetic mellitus, hypertension, smoking, stent diameter, stent length and treatment therapy, were unseen that might be attributed to the small sample size. So, larger sample size studies should be further investigated to verify the correlation between epicardial adipose tissue and ISR. Second, we were unable to identify the precise mechanism by which EAT accumulation could contribute to ISR. However, our results showed that serum lipid and glucose were not elevated in both groups, this might suggested that serum lipid and glucose were good controlled and the progression of ISR might be attributed to systemic inflammation, oxidative stress, endothelial injury, smooth muscle cell proliferation and migration and microphage infiltration may also play a role in the process of ISR. Third, CCTA has the potential risk of radiation exposure, which represents an important consideration. It is unclear whether the benefits of epicardial adipose tissue can overcome the risk of radiation exposure. But, in our study, several techniques such as tube voltage and tube current regulation, prospectively ECG-triggered high-pitch spiral acquisition and heart rate lowing method, were used to better lowering the radiation dose.

This study was supported by grant B13061 from the Scientific Innovation Research Fund of Chinese PLA General Hospital. The authors declared no conflict of interest.

[^1]: The first two authors contributed equally to this manuscript.
